Recursion Pharmaceuticals
RXRX
316 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 114 increasing their positions, 62 reducing their positions, and 34 closing their positions.
153% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 34
84% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 62
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
18% more funds holding
Funds holding: 267 → 316 (+49)
18% more capital invested
Capital invested by funds: $1.74B → $2.06B (+$317M)
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
14.8% less ownership
Funds ownership: 94.22% → 79.42% (-15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$98.6M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.5M |
| 4 |
BlackRock
New York
|
+$18.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$51.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.68M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$6.42M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$5.29M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$5.29M |
RXRX Hedge Fund Activity: Q4 2024 in Review
316 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 86 funds opened new RXRX positions and 34 closed out — a net gain of 52 holders — while 114 added to existing stakes and 62 trimmed.
The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.
- 316 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 267 in Q3 2024.
- Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
- 86 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of +52 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
- The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.
Based on aggregated 13F filings for Q4 2024.